Loading...

GE Healthcare Supply Agreement

SHINE entered into a strategic long‐term supply agreement with GE Healthcare, a division of the General Electric Company, for the supply of molybdenum‐99 (moly‐99). This is the first announcement of a major supply agreement with a U.S. based producer of moly‐99. Under the terms of the supply agreement, SHINE will provide moly‐99 to GE Healthcare on a regular basis once its facility becomes operational.

“GE Healthcare is very pleased to have entered into a long‐term supply agreement with SHINE. The technology represents a significant, safe and viable option for the production of molybdenum‐99 in the future. We believe SHINE will help secure supply for global medical communities and their patients,” said Jan Makela, GM of GE Healthcare Life Sciences Core Imaging.

“Because medical isotopes decay so quickly, it’s essential that the United States establish its own domestic production to meet the needs of our 20 million patients each year. In addition, SHINE will contribute to the strength of the global supply chain,” said Greg Piefer, Ph.D., founder and chief executive officer of SHINE. “By entering into this supply agreement with SHINE, GE Healthcare is effectively affirming that SHINE presents the best new option for western production and a strong option for supply around the globe.”

2017-10-16T08:47:06+00:00